Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,538 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Like Clear all
Recruiting Phase 1 Interventional

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

NCT06450106
View directory record Official record
Conditions
Prostate Cancer
Interventions
STM-416p
Drug
Lead sponsor
SURGE Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Improving Neurodevelopment in Adolescents With Congenital Heart Disease

NCT02759263
View directory record Official record
Conditions
Congenital Heart Disease, Neurodevelopment, Executive Function, Working Memory Training, Infant Open-heart Surgery
Interventions
Cogmed Working Memory Training
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 2 Interventional

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02205528
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus Type 2
Interventions
Liraglutide, Metformin, Placebo, NNC0090-2746
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

Role of Proinflammatory Signaling in Alcohol Craving

NCT01631630
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Drinking, Stress, Alcohol-Related Disorders
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting Not applicable Interventional

Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care

NCT04601064
View directory record Official record
Conditions
HIV Infections, Substance Use Disorders, Mental Health Disorder, Addiction, Opioid Use, Drug Use
Interventions
Collaborative Care Model
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional

The Validity of the Quick Renal MRI in Pediatric Kidney Disease

NCT03959163
View directory record Official record
Conditions
Pyelonephritis, Pyelonephritis Acute, Renal Sclerosis
Interventions
Quick MRI
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Sinus Headache Using a Novel Device That Combines Acoustic Vibration With Oscillating Expiratory Pressure

NCT05479604
View directory record Official record
Conditions
Facial Pain
Interventions
SinuSonic, Sham Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Not applicable Interventional

Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain

NCT02243332
View directory record Official record
Conditions
Patellofemoral Pain Syndrome, Anterior Knee Pain Syndrome
Interventions
KneeStim mobile rehabilitation assistance device
Device
Lead sponsor
Articulate Labs
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

NCT07723833
View directory record Official record
Conditions
Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

NCT00686075
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534, Cohort 1, Placebo, Cohort 1, MEDI-534, Cohort 2, Placebo, Cohort 2, MEDI-534, Cohort 3, Placebo, Cohort 3, MEDI-534, Cohort 4, Placebo, Cohort 4, MEDI-534, Cohort 5, Placebo, Cohort 5
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Months to 23 Months
Enrollment
1,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
51
States / cities
Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901
View directory record Official record
Conditions
Obesity With Diabetes, Overweight With Diabetes
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
62
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

NCT03222973
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BIIB033 (opicinumab), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
51
States / cities
Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
View directory record Official record
Conditions
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
Behavioral · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational

Acute Kidney Injury in Critically Ill Patients

NCT02765464
View directory record Official record
Conditions
Acute Renal Injury
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

RNS® System Feasibility Study

NCT00079781
View directory record Official record
Conditions
Epilepsy
Interventions
RNS® System implantation, RNS® System responsive stimulation
Procedure · Device
Lead sponsor
NeuroPace
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 28, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional

Aesthetic Outcome of Intra-dermal Versus Transcutaneous Purse-string Closure

NCT06448481
View directory record Official record
Conditions
Scarring
Interventions
Intra-dermal purse-string closure, Transcutaneous purse-string closure
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy

NCT02504411
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Device Assisted Colonoscopy, Standard Colonoscopy
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Oct 28, 2026, 6:26 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Intranasal TXA for Anterior Epistaxis in the Emergency Department

NCT04054687
View directory record Official record
Conditions
Epistaxis
Interventions
Tranexamic Acid, Placebo
Drug · Other
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Boardman, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 28, 2026, 6:26 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric Anorexia Study

NCT04858932
View directory record Official record
Conditions
Healthy
Interventions
Continuous Glucose Monitor, Wrist Actigraphy Device, Food Weight Scale, Smart Body Weight Scale
Device
Lead sponsor
Boston University
Other
Eligibility
65 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 28, 2026, 6:26 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

NCT06980623
View directory record Official record
Conditions
Type 2 Diabetes, Heart Failure
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
26,000 participants
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

NCT04935879
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 28, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years

NCT02696148
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
7 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Anaheim, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Oct 28, 2026, 6:26 AM EDT
Terminated Not applicable Interventional

Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease

NCT02521558
View directory record Official record
Conditions
Memory Disorders, Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Intervention Group, Control Group
Behavioral
Lead sponsor
Boston University
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 28, 2026, 6:26 AM EDT